The dosage of the vaccine developed by AstraZeneca in conjunction with the University of Oxford, which showed greater effectiveness – 90% – was tested on volunteers no older than 55 years, in contrast to the dosage with less effectiveness, Bloomberg reported, concerning an adviser to the administration of the current US President Donald Trump on vaccines, Moncef Slaoui.
On Monday, researchers released preliminary results from a phase three clinical trial of a vaccine developed by the University of Oxford and AstraZeneca. The researchers estimated the average effectiveness of vaccination at 70.4%, with minimum effectiveness of 62% and a maximum of 90%. According to the drug’s developer, Andrew Pollard, scientists were more surprised that the vaccine’s effectiveness was higher when patients were first given half the dose and then the vaccine’s full dose. In this case, the developers estimated the effectiveness of the vaccine at 90%. However, when two full doses were administered, the effectiveness was 62%.
Slaoui told reporters that the dosage regimen, in which volunteers first received half the dose and then the full one, was applied to a group no older than 55 years. However, in the group where the volunteers received two full doses, and the vaccine’s effectiveness was 62%, there were people over 55 years of age.
The company’s statement did not give the age of volunteers in different groups.